Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31611850 | 1.00 | PTGS1 (0.50) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30519346 | 0.97 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29597541 | 0.97 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29695453 | 0.97 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL31018947 | 0.97 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30674927 | 0.94 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30692039 | 0.94 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29540545 | 0.90 | PTGS1 (0.43) | PTGS1GSTK1GLO1OPRD1OPRM1 | |
| SCHEMBL30905702 | 0.89 | PTGS1 (0.64) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30733592 | 0.89 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725503-A2 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | University Of Southern California (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4592310-A2 | NOVEL ANTIGEN BINDING DOMAINS AND SYNTHETIC ANTIGEN RECEPTORS INCORPORATING THE SAME | Angeles Therapeutics, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12371470-B2 | Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen | HEALTH RESEARCH, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250177513-A1 | RABIES G PROTEIN AND USES THEREOF | ICOSAVAX, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12275946-B2 | Compositions and methods for rapid cloning of t-cell receptors | HEALTH RESEARCH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12269859-B2 | Synthetic immune receptors and methods of use thereof | ANGELES THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250057881-A1 | COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS AGAINST CLAUDIN 6 | ROSWELL PARK CANCER INST CORPORATION (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119119176-A | Camptothecin derivatives | 伊缪诺金公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240390496-A1 | SINGLE-CHAIN AND MULTI-CHAIN SYNTHETIC ANTIGEN RECEPTORS FOR DIVERSE IMMUNE CELLS | CHAUDHARY, PREET M, DR. | 2024-11-28 | — | — | US | disclosed |
| WO-2022178367-A2 | SINGLE-CHAIN AND MULTI-CHAIN SYNTHETIC ANTIGEN RECEPTORS FOR DIVERSE IMMUNE CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220204582-A1 | SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF | ANGELES THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-113563430-B | Gene delivery system for treating ocular diseases and uses thereof | 上海信致医药科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-113480615-B | Novel adeno-associated virus capsid protein with high retinal affinity and application thereof | 上海信致医药科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-109804246-B | Compositions and methods for rapid cloning of T cell receptors | 健康研究公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220135678-A1 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES | NATIONAL INSTITUTES OF HEALTH | 2022-05-05 | — | — | US | disclosed |
| US-20220127595-A1 | CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS | BIOATLA, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3399985-B1 | COMPOSITIONS AND LIBRARIES COMPRISING RECOMBINANT T-CELL RECEPTORS AND METHODS OF USING RECOMBINANT T-CELL RECEPTORS | HEALTH RESEARCH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371470-B2 | Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen | CD4, CD74, MICA | PTGS1 3007/4885GSTK1 1154/4885GLO1 4793/4885 |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | PTGS1 3190/4885GSTK1 584/4885GLO1 4846/4885 |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | PTGS1 2344/4885GSTK1 62/4885GLO1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.